Potency and safety analysis of hemp-derived delta-9 products: The hemp vs. cannabis demarcation problem
Posted on November 28, 2023 By LabLynx Journal articles
Contents
Edit links
Tools
Actions
General
- What links here
- Related changes
- Upload file
- Special pages
- Permanent link
- Page information
- Cite this page
- Get shortened URL
- Download QR code
Print/export
- Download as PDF
- Printable version
In other projects
- Wikimedia Commons
- Wikidata item
Appearance
Chemical compound
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider |
|
UNII | |
KEGG |
|
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C25H25Cl2N7O |
Molar mass | 510.42 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
Otenabant (CP-945,598) is a drug that acts as a potent and highly selective CB1 antagonist.[1] It was developed by Pfizer for the treatment of obesity,[2] but development for this application has been discontinued following the problems seen during clinical use of the similar drug rimonabant.[3]
See also
References
- ^ Kim MA, Yun H, Kwak H, Kim J, Lee J (2008). "Design, chemical synthesis, and biological evaluation of novel triazolyl analogues of taranabant (MK-0364), a cannabinoid-1 receptor inverse agonist". Tetrahedron. 64 (48): 10802–10809. doi:10.1016/j.tet.2008.09.057.
- ^ Woods SC (November 2007). "The endocannabinoid system: novel pathway for cardiometabolic Risk-factor reduction". Journal of the American Academy of Physician Assistants. Suppl Endocannabinoid (11): 7–10. doi:10.1097/01720610-200711000-00005. PMID 18047036. S2CID 25472128.
- ^ "Pfizer Pharmaceutical News and Media - Pfizer: One of the world's premier biopharmaceutical companies". www.pfizer.com.
Phytocannabinoids (comparison) |
| ||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Endocannabinoids |
| ||||||||||||||||||||||||||||||||||||||||
Synthetic cannabinoid receptor agonists / neocannabinoids |
| ||||||||||||||||||||||||||||||||||||||||
Allosteric CBRTooltip Cannabinoid receptor ligands | |||||||||||||||||||||||||||||||||||||||||
Endocannabinoid enhancers (inactivation inhibitors) |
| ||||||||||||||||||||||||||||||||||||||||
Anticannabinoids (antagonists/inverse agonists/antibodies) |
| ||||||||||||||||||||||||||||||||||||||||
|
Receptor (ligands) |
| ||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Transporter (modulators) |
| ||||||||||||||||||||||||||||||
Enzyme (modulators) |
| ||||||||||||||||||||||||||||||
Others |
| ||||||||||||||||||||||||||||||
|
by LabLynx